AC Immune (ACIU) Downgraded by Zacks Investment Research

AC Immune (NASDAQ:ACIU) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “

Several other equities research analysts also recently weighed in on ACIU. BidaskClub raised AC Immune from a “hold” rating to a “buy” rating in a report on Monday, June 18th. ValuEngine raised AC Immune from a “hold” rating to a “buy” rating in a report on Friday, July 6th. Finally, HC Wainwright set a $18.00 price target on AC Immune and gave the stock a “buy” rating in a report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $14.00.

Shares of NASDAQ ACIU opened at $7.98 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.65 and a quick ratio of 9.65. AC Immune has a 1-year low of $7.16 and a 1-year high of $17.40. The firm has a market cap of $526.90 million, a P/E ratio of -26.60 and a beta of 2.22.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. AC Immune had a negative return on equity of 25.44% and a negative net margin of 133.00%. The firm had revenue of $2.03 million during the quarter, compared to the consensus estimate of $1.92 million. On average, sell-side analysts predict that AC Immune will post -0.93 earnings per share for the current fiscal year.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Featured Story: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with's FREE daily email newsletter.

Leave a Reply